Randomized phase II study of two induction treatments of melphalan, prednisolone, plus bortezomib, JCOG-MPB versus modified PETHEMA-MPB, in elderly patients or non-elderly patients refusing transplant with untreated symptomatic myeloma (JCOG1105, IMPROVE-MPB study)

Trial Profile

Randomized phase II study of two induction treatments of melphalan, prednisolone, plus bortezomib, JCOG-MPB versus modified PETHEMA-MPB, in elderly patients or non-elderly patients refusing transplant with untreated symptomatic myeloma (JCOG1105, IMPROVE-MPB study)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 May 2016

At a glance

  • Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Melphalan (Primary) ; Prednisolone (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms IMPROVE-MPB
  • Most Recent Events

    • 11 May 2016 Status changed from recruiting to active, no longer recruiting.
    • 25 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top